Investing Videos

Buying Time With Drugs || Peter Zeihan

Peter Zeihan examines whether emerging anti‑aging or anti‑Alzheimer’s drugs can alter the demographic trajectory of the United States and China. He focuses on the urgency of extending productive life spans to offset retiring baby‑boomers and shrinking labor pools. Zeihan notes that monoclonal‑antibody therapies, while scientifically impressive, only slow cognitive decline by roughly 30 % over an 18‑month trial and cost prohibitive amounts. Even if such drugs became affordable, the timing is off: the bulk of the baby‑boom cohort is already past retirement age, and Gen X lacks the numbers to shift the needle significantly. He also mentions weight‑loss agents like Ozempic, which could reduce inflammation and improve health, but they have only a few years of safety data and remain expensive. Key quotations include, “they only reduce cognitive decline by 30 % over 18 months,” and the observation that “we need to push retirement age to at least 70 to keep the tax base viable.” Zeihan points to Korea and Scandinavia, where lifelong exercise, diet, and emotional well‑being have produced the longest, healthiest lives, as the only proven model. The implication is clear: policymakers cannot bank on a pharmaceutical breakthrough to solve aging‑related labor shortages. Instead, they must invest in preventive health, lifestyle education, and structural reforms to retirement age, lest fiscal pressures from an aging populace overwhelm economies.